Covered recipient · General Payments record
NICHOLAS PATRICK MCANDREW
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$854.83
4 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $685.00 | 1 |
| Food and Beverage | $169.83 | 3 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $685.00 | 1 |
| E.R. Squibb & Sons, L.L.C. | $116.94 | 1 |
| BeiGene USA, Inc. | $52.89 | 2 |
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
NICHOLAS PATRICK MCANDREW
NPI 1093074106 · CMS profile ID 906526
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
LOS ANGELES, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1093074106?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- NICHOLAS PATRICK MCANDREW, NPI 1093074106, CMS profile ID 906526. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093074106?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). NICHOLAS PATRICK MCANDREW, NPI 1093074106, CMS profile ID 906526. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093074106?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- NICHOLAS PATRICK MCANDREW, NPI 1093074106, CMS profile ID 906526, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1093074106?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
4 matching records · $854.83 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–4 of 4.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| BeiGene USA, Inc. | $29.12 | 12/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051196613 | CMS |
| BeiGene USA, Inc. | $23.77 | 11/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051196611 | CMS |
| E.R. Squibb & Sons, L.L.C. | $116.94 | 10/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016293335 | CMS |
| AstraZeneca Pharmaceuticals LP | $685.00 | 03/16/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011434723 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $872.20 | 1 |
| PY2025 | Principal investigator | $596,816.77 | 153 |
| PY2024 | Recipient | $1,633.83 | 1 |
| PY2024 | Principal investigator | $3,352,829.60 | 63 |
| PY2023 | Recipient | $1,409.82 | 1 |
| PY2023 | Principal investigator | $2,151,571.63 | 67 |
| PY2022 | Principal investigator | $2,868,775.41 | 36 |
| PY2021 | Principal investigator | $3,830,116.22 | 25 |
| PY2020 | Principal investigator | $6,585,760.41 | 40 |
| PY2019 | Principal investigator | $3,438,563.63 | 29 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
64 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $14,302.00 | 12/30/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 | No dispute reported | 06/30/2026 | 1130932044 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $47,411.36 | 12/19/2024 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A multicenter phase 1b trial evaluating the safety of Ribociclib, Tucatinib, and Trastuzumab in patients with metastatic HER2+ breast cancer and a multicenter, randomized, open label, phase 2 study of preoperative treatment with Ribicliclib, Trastuzumab | No dispute reported | 06/30/2026 | 1089696331 |
| Principal investigator 1 | PFIZER INC. | $867.00 | 12/16/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 | No dispute reported | 06/30/2026 | 1130900190 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $76,858.20 | 12/13/2024 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | DS8201-A-U301 | No dispute reported | 06/30/2026 | 1145040562 |
| Principal investigator 1 | PFIZER INC. | $138,829.21 | 12/09/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A PHASE 1B TRIAL EVALUATING THE SAFETY OF RIBOCICLIB TUCATINIB AND TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2 BREAST CANCER AND A MULTICENTER RANDOMIZED OPENLABEL PHASE 2 STUDY OF PREOPERATIVE TREATMENT WITH RIBOCICLIB TRASTUZUMAB TUCATINIB AND FULVESTRANT VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN HRHER2 BREAST CANCER AND RIBOCICLIB TRASTUZUMAB AND TUCATINIB VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN PATIENTS WITH HRHER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130914687 |
| Principal investigator 1 | PFIZER INC. | $17,334.00 | 12/09/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 | No dispute reported | 06/30/2026 | 1130932464 |
| Principal investigator 1 | Eli Lilly and Company | $20,020.50 | 11/14/2024 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A STUDY OF LOXO-783 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ANTICANCER THERAPIES FOR PATIENTS WITH ADVANCED BREAST CANCER AND OTHER SOLID TUMORS WITH A PIK3CA H1047R MUTATION | No dispute reported | 06/30/2026 | 1137351834 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $397,580.10 | 11/07/2024 | Non-covered Recipient Entity David Geffen School of Medicine at the University of California | 2019-ESR-00133 | No dispute reported | 06/30/2026 | 1145040258 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $390,183.35 | 10/31/2024 | Non-covered Recipient Entity David Geffen School of Medicine at the University of California | 2019-ESR-00133 | No dispute reported | 06/30/2026 | 1145040256 |
| Principal investigator 1 | PFIZER INC. | $41,773.58 | 10/09/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A PHASE 1B TRIAL EVALUATING THE SAFETY OF RIBOCICLIB TUCATINIB AND TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2 BREAST CANCER AND A MULTICENTER RANDOMIZED OPENLABEL PHASE 2 STUDY OF PREOPERATIVE TREATMENT WITH RIBOCICLIB TRASTUZUMAB TUCATINIB AND FULVESTRANT VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN HRHER2 BREAST CANCER AND RIBOCICLIB TRASTUZUMAB AND TUCATINIB VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN PATIENTS WITH HRHER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130933007 |
| Principal investigator 1 | PFIZER INC. | $15,027.00 | 09/26/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 | No dispute reported | 06/30/2026 | 1130933003 |
| Principal investigator 1 | PFIZER INC. | $867.00 | 09/26/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130933014 |
| Principal investigator 1 | PFIZER INC. | $128,150.04 | 09/12/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A PHASE 1B TRIAL EVALUATING THE SAFETY OF RIBOCICLIB TUCATINIB AND TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2 BREAST CANCER AND A MULTICENTER RANDOMIZED OPENLABEL PHASE 2 STUDY OF PREOPERATIVE TREATMENT WITH RIBOCICLIB TRASTUZUMAB TUCATINIB AND FULVESTRANT VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN HRHER2 BREAST CANCER AND RIBOCICLIB TRASTUZUMAB AND TUCATINIB VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN PATIENTS WITH HRHER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130932926 |
| Principal investigator 1 | PFIZER INC. | $600.00 | 09/11/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130930243 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $349.00 | 08/19/2024 | Non-covered Recipient Entity UCLA MEDICAL CENTER | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1089690129 |
| Principal investigator 1 | PFIZER INC. | $10,621.66 | 08/13/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 | No dispute reported | 06/30/2026 | 1130929302 |
| Principal investigator 1 | PFIZER INC. | $21,358.34 | 08/13/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 | No dispute reported | 06/30/2026 | 1130930251 |
| Principal investigator 1 | PFIZER INC. | $21,358.34 | 08/09/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 | No dispute reported | 06/30/2026 | 1130933022 |
| Principal investigator 1 | PFIZER INC. | $5,481.00 | 08/07/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130933034 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $390,183.35 | 07/24/2024 | Non-covered Recipient Entity David Geffen School of Medicine at the University of California | 2019-ESR-00133 | No dispute reported | 06/30/2026 | 1145040254 |
| Principal investigator 1 | PFIZER INC. | $20,764.00 | 07/24/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 | No dispute reported | 06/30/2026 | 1130928956 |
| Principal investigator 1 | PFIZER INC. | $4,135.00 | 07/24/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130928960 |
| Principal investigator 1 | PFIZER INC. | $128,150.04 | 07/02/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A PHASE 1B TRIAL EVALUATING THE SAFETY OF RIBOCICLIB TUCATINIB AND TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2 BREAST CANCER AND A MULTICENTER RANDOMIZED OPENLABEL PHASE 2 STUDY OF PREOPERATIVE TREATMENT WITH RIBOCICLIB TRASTUZUMAB TUCATINIB AND FULVESTRANT VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN HRHER2 BREAST CANCER AND RIBOCICLIB TRASTUZUMAB AND TUCATINIB VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN PATIENTS WITH HRHER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130933010 |
| Principal investigator 1 | PFIZER INC. | $11,340.00 | 06/20/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 | No dispute reported | 06/30/2026 | 1130932938 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,543.56 | 06/19/2024 | Non-covered Recipient Entity David Geffen School of Medicine at the University of California | 2019-ESR-00133 | No dispute reported | 06/30/2026 | 1145040252 |
| Principal investigator 1 | PFIZER INC. | $21,243.32 | 06/18/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 | No dispute reported | 06/30/2026 | 1130932896 |
| Principal investigator 1 | Veru Inc. | $110,981.00 | 06/18/2024 | Non-covered Recipient Entity The Regents of the University of California on behalf of its Los Angeles campus | VERU_V3002401_4063_01 | No dispute reported | 06/30/2026 | 1150702450 |
| Principal investigator 1 | PFIZER INC. | $41,773.58 | 06/12/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A PHASE 1B TRIAL EVALUATING THE SAFETY OF RIBOCICLIB TUCATINIB AND TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2 BREAST CANCER AND A MULTICENTER RANDOMIZED OPENLABEL PHASE 2 STUDY OF PREOPERATIVE TREATMENT WITH RIBOCICLIB TRASTUZUMAB TUCATINIB AND FULVESTRANT VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN HRHER2 BREAST CANCER AND RIBOCICLIB TRASTUZUMAB AND TUCATINIB VERSUS DOCETAXEL CARBOPLATIN TRASTUZUMAB AND PERTUZUMAB IN PATIENTS WITH HRHER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130929628 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $157,202.64 | 06/11/2024 | Non-covered Recipient Entity UCLA HEMATOLOGY ONCOLOGY BEV HILLS | A multicenter phase 1b trial evaluating the safety of Ribociclib, Tucatinib, and Trastuzumab in patients with metastatic HER2+ breast cancer and a multicenter, randomized, open label, phase 2 study of preoperative treatment with Ribicliclib, Trastuzumab | No dispute reported | 06/30/2026 | 1089690415 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $397,580.10 | 05/30/2024 | Non-covered Recipient Entity David Geffen School of Medicine at the University of California | 2019-ESR-00133 | No dispute reported | 06/30/2026 | 1145040250 |
| Principal investigator 1 | PFIZER INC. | $1,156.00 | 05/22/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130933030 |
| Principal investigator 1 | PFIZER INC. | $800.00 | 05/15/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130929901 |
| Principal investigator 1 | PFIZER INC. | $9,079.00 | 05/15/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 | No dispute reported | 06/30/2026 | 1130932627 |
| Principal investigator 1 | PFIZER INC. | $1,156.00 | 04/24/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130929632 |
| Principal investigator 1 | PFIZER INC. | $3,764.00 | 04/10/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130930247 |
| Principal investigator 1 | PFIZER INC. | $24,287.00 | 03/27/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 | No dispute reported | 06/30/2026 | 1130929890 |
| Principal investigator 1 | PFIZER INC. | $8,755.00 | 03/20/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130930382 |
| Principal investigator 1 | PFIZER INC. | $4,652.00 | 03/13/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 | No dispute reported | 06/30/2026 | 1130930059 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $8,673.00 | 02/29/2024 | Non-covered Recipient Entity UCLA HEM ONCOLOGY LAGUNA HILLS | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1089690161 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,200.00 | 02/29/2024 | Non-covered Recipient Entity UCLA HEALTH HEMATOLOGY ONCOLOGY ENCINO | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1089690199 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,675.00 | 02/29/2024 | Non-covered Recipient Entity UCLA BURBANK | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1089690379 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,870.00 | 02/29/2024 | Non-covered Recipient Entity UCLA HEMATOLOGY ONCOLOGY BEV HILLS | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1089690421 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,531.00 | 02/29/2024 | Non-covered Recipient Entity UCLA HEALTH PASADENA CANCER CARE | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1089690451 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,055.00 | 02/29/2024 | Non-covered Recipient Entity UCLA VALENCIA | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1089691045 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,342.00 | 02/29/2024 | Non-covered Recipient Entity UCLA HEALTH HEMATOLOGY ONCOLOGY | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1089697479 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $113,254.03 | 02/14/2024 | Non-covered Recipient Entity UCLA HEALTH SANTA MONICA CANCER CARE | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1089689699 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $397,580.10 | 02/13/2024 | Non-covered Recipient Entity David Geffen School of Medicine at the University of California | 2019-ESR-00133 | No dispute reported | 06/30/2026 | 1145040248 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $38,750.34 | 02/08/2024 | Non-covered Recipient Entity UCLA WESTLAKE VILLAGE PRIMARY AND SPECIALTY CARE | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1089689995 |
| Principal investigator 1 | PFIZER INC. | $24,357.00 | 02/07/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130933018 |
| Recipient | Novartis Pharmaceuticals Corporation | $1,633.83 | 02/06/2024 | Covered Recipient Physician | CLEE011O12301C | No dispute reported | 06/30/2026 | 1089690037 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,534.00 | 02/02/2024 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | DS8201-A-U303 | No dispute reported | 06/30/2026 | 1145040590 |
| Principal investigator 1 | PFIZER INC. | $578.00 | 02/01/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130929476 |
| Principal investigator 1 | PFIZER INC. | $517.86 | 02/01/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | STUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC HER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130930386 |
| Principal investigator 1 | PFIZER INC. | $7,678.00 | 01/18/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 | No dispute reported | 06/30/2026 | 1130932638 |
| Principal investigator 1 | PFIZER INC. | $10,220.00 | 01/11/2024 | Covered Recipient Teaching Hospital RESNICK NEUROPSYCHIATRIC HOSPITAL AT | A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1130930063 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $20.00 | 01/03/2024 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | DS8201-A-U303 | No dispute reported | 06/30/2026 | 1086069862 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $63.00 | 01/03/2024 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | DS8201-A-U303 | No dispute reported | 06/30/2026 | 1086069864 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $204.00 | 01/03/2024 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | DS8201-A-U303 | No dispute reported | 06/30/2026 | 1086069866 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $378.00 | 01/03/2024 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | DS8201-A-U303 | No dispute reported | 06/30/2026 | 1086069868 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,650.00 | 01/03/2024 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | DS8201-A-U303 | No dispute reported | 06/30/2026 | 1086069870 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,488.00 | 01/03/2024 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | DS8201-A-U303 | No dispute reported | 06/30/2026 | 1086069872 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $9,429.00 | 01/03/2024 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | DS8201-A-U303 | No dispute reported | 06/30/2026 | 1086069874 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $11,712.00 | 01/03/2024 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | DS8201-A-U303 | No dispute reported | 06/30/2026 | 1086069876 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $14,553.00 | 01/03/2024 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | DS8201-A-U303 | No dispute reported | 06/30/2026 | 1086069878 |